ADC Therapeutics SA EPS - Earnings per Share 2019-2023 | ADCT
ADC Therapeutics SA eps - earnings per share from 2019 to 2023. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| ADC Therapeutics SA Annual EPS |
| 2022 |
$-1.99 |
| 2021 |
$-3.00 |
| 2020 |
$-3.77 |
| 2019 |
$-2.36 |
| 2018 |
$-2.64 |
| ADC Therapeutics SA Quarterly EPS |
| 2023-03-31 |
$-0.74 |
| 2022-12-31 |
$-0.28 |
| 2022-09-30 |
$-0.65 |
| 2022-06-30 |
$-0.84 |
| 2022-03-31 |
$-0.22 |
| 2021-12-31 |
$-0.45 |
| 2021-09-30 |
$-0.93 |
| 2021-06-30 |
$-0.95 |
| 2021-03-31 |
$-0.67 |
| 2020-12-31 |
$-0.62 |
| 2020-09-30 |
$-0.29 |
| 2020-06-30 |
$-2.01 |
| 2020-03-31 |
$-0.85 |
| 2019-12-31 |
$0.00 |
| 2019-09-30 |
$-0.62 |
| 2019-06-30 |
$-0.49 |
| 2018-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.175B |
$0.210B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
